CAPTAIN STUDY: TREATMENT OUTCOMES FROM FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL ACCORDING TO HISTORY OF SEVERE ASTHMA EXACERBATIONS

被引：0
|
作者：
Oppenheimer, J.
Brusselle, G.
Busse, W.
Fowler, A.
Jain, N.
Mannino, D.
Pavord, I.
Win, P.
Zarankaite, A.
Kerwin, E.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2020年 / 125卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P202
引用
收藏
页码：S26 / S27
页数：2
相关论文
共 50 条
  • [1] CAPTAIN STUDY: EFFECTS OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL ON FEV1 IMPROVEMENT IN ASTHMA ACCORDING TO AGE
    Hanania, N.
    Bailes, Z.
    Barnes, N.
    Gardiner, F.
    Lugogo, N.
    Mannino, D.
    Mehta, V.
    Nyanjom, D.
    Sitz, K.
    Kerstjens, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S28 - S28
  • [2] Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study
    Nakamura, Yoichi
    Hozawa, Soichiro
    Sagara, Hironori
    Ohbayashi, Hiroyuki
    Lee, Laurie A.
    Crawford, Jodie
    Tamaoki, Jun
    Nishi, Takanobu
    Fowler, Andrew
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (09) : 1657 - 1665
  • [3] Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN)
    Yang, Shuying
    Lee, Laurie A.
    Sule, Neal
    Fowler, Andrew
    Peachey, Guy
    CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 887 - 896
  • [4] The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status
    Halpin, D. M. G.
    Bardsley, S.
    Criner, G.
    Dransfield, M.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lomas, D. A.
    Martinez, F.
    Pascoe, S.
    Singh, D.
    Wise, R.
    Lipson, D. A.
    Lange, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [5] Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN)
    Shuying Yang
    Laurie A. Lee
    Neal Sule
    Andrew Fowler
    Guy Peachey
    Clinical Pharmacokinetics, 2021, 60 : 887 - 896
  • [6] The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: A Pre-Specified Analysis of Safety According to Age
    Criner, G. J.
    Dransfield, M.
    Halpin, D. M. G.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F.
    Pascoe, S.
    Singh, D.
    Wise, R.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [7] Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
    Day, Nicola C.
    Kumar, Subramanya
    Criner, Gerard
    Dransfield, Mark
    Halpin, David M. G.
    Han, MeiLan K.
    Jones, C. Elaine
    Kaisermann, Morrys C.
    Kilbride, Sally
    Lange, Peter
    Lomas, David A.
    Martin, Neil
    Martinez, Fernando J.
    Singh, Dave
    Wise, Robert
    Lipson, David A.
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [8] Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
    Nicola C. Day
    Subramanya Kumar
    Gerard Criner
    Mark Dransfield
    David M. G. Halpin
    MeiLan K. Han
    C. Elaine Jones
    Morrys C. Kaisermann
    Sally Kilbride
    Peter Lange
    David A. Lomas
    Neil Martin
    Fernando J. Martinez
    Dave Singh
    Robert Wise
    David A. Lipson
    Respiratory Research, 21
  • [9] FLUTICASONE FUROATE/VILANTEROL COMBINATION FOR THE TREATMENT OF ASTHMA AND COPD
    Rogliani, P.
    Matera, M. G.
    Cazzola, M.
    DRUGS OF TODAY, 2015, 51 (08) : 469 - 478
  • [10] A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD
    Cazzola, Mario
    Rogliani, Paola
    Calzetta, Luigino
    Ora, Josuel
    Matera, Maria Gabriella
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (03) : 269 - 283
12345